Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …

Background & Aims Alpha-fetoprotein (AFP) predicts hepatocellular carcinoma (HCC)
recurrence after liver transplant (LT) but remains an imperfect biomarker. The role of DCP …

In patients with HCC awaiting liver transplantation (LT), there is a need to identify
biomarkers that are superior to AFP in predicting prognosis. AFP-L3 and des-gamma …

Objective: To evaluate long-term oncologic outcomes of patients post–living donor liver
transplantation (LDLT) within and outside standard transplantation selection criteria and the …

HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict
patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains …

Hepatocellular carcinoma (HCC) is one of the leading indications for liver transplantation
and has been the treatment of choice due to the oncologic benefit for patients with advanced …

Abstract Elevated Protein Induced by Vitamin-K Absence-II (PIVKA-II) has been shown to be
an adverse prognostic factor in HCC patients undergoing liver transplantation (LT). No …